MAPT and Alzheimer disease: (4) Although AD core CSF biomarkers of amyloid, phospho-tau and total tau are currently well validated measures of AD pathology, this study should be replicated using modern neuroimaging techniques such as in vivo amyloid and Tau PET 5) Lastly, due to practical reasons, (i.e., clinical progression to dementia which limits the possibility for memory clinic visits), we applied a relatively short follow-up period with a mean of 2.5 years, implying that a certain proportion of patients who were classified as stable are likely to progress to dementia later on.